

ALL CANCER (EXCLUDING NMSC)



AVERAGE NUMBER OF CASES PER YEAR (2012-2016) ¹			AVERAGE NUMBER OF DEATHS PER YEAR (2012-2016)		
Male	Female	Both sexes	Male	Female	Both sexes
4,607	4,632	9,240 ¹	2,238	2,036	4,274
FIVE-YEAR SURVIVAL (2006-2010)			24-YEAR PREVALENCE (2016)		
Male	Female	Both sexes	Male	Female	Both sexes
53.1%	56.4%	55.1%	26,686	34,352	61,038

¹ Mean yearly incidence data for period 2012-2016 has been rounded to nearest integer, and thus some numbers in tables will not add to give the exact total.

INCIDENCE

From 2012 to 2016, on average, there were 4,607 male and 4,632 female patients diagnosed with cancer each year excluding Non-Melanoma Skin Cancer (NMSC). There were an additional 2,124 male and 1,594 female patients diagnosed with NMSC. The lifetime risk of developing a cancer (excluding NMSC) was 1 in 3.5 for men and 1 in 3.7 for women.


Incidence trends

Table 1: Incidence of cancer by sex and year of diagnosis: 2007-2016

	2007	2008	2009	2010	2012	2012	2013	2014	2015	2016
Male	4,044	4,181	4,219	4,156	4,483	4,520	4,529	4,614	4,745	4,629
Female	3,885	4,075	4,127	4,110	4,328	4,488	4,561	4,583	4,712	4,817
Both sexes	7,929	8,256	8,346	8,266	8,811	9,008	9,090	9,197	9,457	9,446

Over the last ten years the number of cancer cases (excluding non melanoma skin cancers) increased between 2007 and 2016 from 4,044 to 4,629 among men and 3,885 to 4,817 among women. This increase of 15% in men and 24% in women (19% overall) is largely due to increasing numbers of older people in the population. After accounting for our aging population, cancer incidence rates increased among males during 1999-2011 by an average of 1.1% per year, followed by a decrease of 1.5% between 2011-2016. From 2001-2016, female incidence rates increased steadily by an average of 1.0% per year.

Figure 1: Trends in cancer incidence rates by sex: 1993-2016



Incidence and age


The risk of developing cancer increases with age, with over 60% of cancers occurring in those aged over 65 and incidence rates greatest for those aged 80-89 in both men and women.

Table 2: Average number of cancers diagnosed per year by sex and age: 2012-2016

Age (years)	Male	Female	Total
0 to 49	385	698	1,083
50 to 64	1,144	1,247	2,391
65 to 74	1,491	1,173	2,664
75 and over	1,587	1,514	3,102
All ages	4,607	4,632	9,240

Due to rounding of yearly averages, 'All ages' may not equal the sum of age categories in tables.

Figure 2: Incidence of cancer by age and sex: 2012-2016



Cancer site

Cancer can occur in many different parts of the body, some more common than others and with considerable variation between males and females. The most common cancers among males between 2012 and 2016 were prostate, colorectal, lung, head & neck and lymphomas (Fig. 3) while the most common cancers among women were breast, lung, colorectal and uterine cancer (Fig. 4).

Figure 3: The most common cancers (excluding NMSC) diagnosed in men: annual incidence 2012-2016





Figure 4: The most common cancers (excluding NMSC) diagnosed in women: annual incidence 2012-2016



Age at diagnosis by cancer site 2012-2016

Age at diagnosis varied by cancer site. Overall half of cancer patients were diagnosed before the age of 69 years (median age) with median age at diagnosis higher among males (70 years) than females (68 years). In men, the median age ranged from 35 years for testicular cancer to 75 years for bladder cancer. In women, the median age ranged from 41 years for cervical cancer to 78 years for stomach cancer. The most common cancers, breast cancer among females and prostate cancer among males, had a median age at diagnosis of 63 years and 70 years, respectively.

Figure 5: The median age of male cancer patients by cancer site






Figure 6: The median age of female cancer patients by cancer site



Incidence by Trust area

Incidence rates of cancer (excluding NMSC) in 2012-2016 were 8% higher among people living in Belfast HSC Trust area than the NI average. Rates were lower than the NI average for those living in the South-Eastern Trust area.

Figure 7: Cancer incidence rates compared to the NI average by sex and HSC Trust of residence: 2012-2016



© Crown Copyright and database rights NIMA MOU207.2

Significantly higher than average

Significantly lower than average

Incidence by deprivation

Some geographical variation is due to a relationship between cancer and socio-economic deprivation. Cancer incidence is higher in the most deprived communities in Northern Ireland though this varies significantly by cancer site. Incidence of cancer of the head & neck, oesophagus, stomach, lung, pancreas, male-colorectal, and cervix are higher in more deprived areas while incidence of breast, melanoma, non-melanoma skin and prostate cancer are higher in the least deprived communities.

Figure 8: All cancer incidence rates compared to the NI average by sex and deprivation quintile: 2012-2016




Table 3: The relationship between cancer incidence rates and socio-economic deprivation

Incidence rates higher in deprived than affluent areas	No significant relationship	Incidence rates higher in affluent than deprived areas
Head & neck, oesophagus, stomach, lung, pancreas, male-colorectal, cervix	Kidney, Liver, Myeloma, Uterus, Ovary, Testes, Lymphoma, Leukaemia, Bladder	Breast, Melanoma, Non-melanoma skin, Prostate

SURVIVAL

Overall survival

The net survival was 70.5% at one year, and 55.1% at five years for patients diagnosed in 2006 to 2010.

Table 4: Five-year survival by sex: patients diagnosed 2006-2010

Time since diagnosis	Diagnosed 2006-2010		
	Male	Female	Both sexes
6 months	76.9%	78.0%	77.6%
1 year	69.2%	71.5%	70.5%
5 years	53.1%	56.4%	55.1%

Survival Trends

Five-year net survival from cancer has improved, increasing from 38.3% to 53.1% for men and from 48.0% to 56.4% for women, when we compare patients diagnosed from 1993 to 2000 to those diagnosed from 2006 to 2010.

Table 6: Five-year survival by period of diagnosis and sex

Period of diagnosis	Male	Female	Both sexes
1993-2000	38.3%	48.0%	43.6%
2001-2005	47.0%	52.7%	50.2%
2006-2010	53.1%	56.4%	55.1%

Survival and cancer site

Survival varied by cancer site with estimates of five-year (age-standardised) net survival for male patients diagnosed 2006-2010 ranging from 5.0% for pancreatic cancer to 97.8% for testicular cancer. Among females five-year (age-standardised) net survival ranged from 4.9% for pancreatic cancer to 92.8% for non-invasive brain cancer. Comparisons of five-year survival for patients diagnosed 2005-2009 to those diagnosed 1993-2000 show survival improvements for all cancers except bladder cancer in both females and males. Three (breast, colorectal and prostate) of the four most common cancers showed strong improvement.

Table 7: Five-year age-standardised net survival of patients diagnosed 2006-2010 compared to patients diagnosed 1993-2000 by site

Site (ICD10 code ¹)	1993-2000		2006-2010	
	Male	Female	Male	Female
All Cancers excluding NMSC (C00-C43,C45-C97)	38.3%	48.0%	53.1%	56.4%
Bladder (C67)	59.9%	48.5%	57.6%	43.4%
Brain and other CNS (C70-C72,C75.1-C75.3)	16.3%	22.0%	24.0%	24.8%
Breast (C50)	-	75.9%	-	81.7%
Cervix (C53)	-	58.4%	-	63.0%
Childhood cancer (C00-C97,ex C44)	73.6% ³	75.1% ³	76.4% ³	84.2% ³
Colon (C18)	50.5%	52.1%	57.3%	58.0%
Colorectal (C18-C20)	49.6%	51.1%	56.9%	58.6%
Head and Neck (C00-C14; C30-C32)	53.0%	48.1%	54.4%	56.0%
Hodgkin Lymphoma (C81)	75.9% ³	78.2% ³	86.9% ³	73.8% ³
Kidney (C64)	49.3%	51.2%	56.9%	54.7%
Leukaemia (C91-C95)	34.1%	35.2%	52.0%	54.8%
Lip, Oral Cavity & Pharynx (C00-C14)	46.2%	42.3%	51.3%	52.5%
Liver & Intrahepatic Bile Ducts (C22)	4.9%	4.9%	6.7%	10.7%
Lung, Bronchus & Trachea (C33-C34)	8.0%	9.4%	10.1%	11.0%
Lymphoma (C81-C86)	44.6%	49.8%	62.1%	66.7%
Malignant Melanoma (C43)	85.5%	90.8%	89.6%	92.0%
Multiple Myeloma (C90)	27.3%	35.0%	49.3%	51.6%
Non-Hodgkin Lymphoma (C82-C85)	42.3%	48.8%	60.2%	66.9%
Non-Invasive Brain (D32,D33.0-D33.4,D35.2-D35.4,D42,D43.0-D43.4,D44.3-D44.5)	87.2%	85.9%	90.7%	92.8%
Oesophagus (C15)	8.9%	15.8%	19.2%	20.3%
Ovary (including fallopian tube and ligaments) (C56-C57.7)	-	36.9%	-	40.8%
Pancreas (C25)	2.2%	2.7%	5.0%	4.9%
Prostate (C61)	63.5%	-	88.7%	-
Rectum (C19-C20)	47.4%	48.4%	56.0%	59.9%
Stomach (C16)	15.6%	17.2%	18.6%	21.2%
Testis (C62)	94.5% ³	-	97.8% ³	-
Ill defined, secondary and unspecified sites (C76-C80)	6.8%	9.7%	11.6%	10.4%
Uterus body (endometrium) (C54-C55)	-	64.7%	-	77.6%

1 The classification of different tumours codes see: International Statistical Classification of Diseases and Related Health Problem to cancer types, e.g. lung is done using ICD10 codes. For a listing and explanation of ICD10 topography or site s, Tenth Revision, World Health Organisation, Geneva. Or view online at <http://apps.who.int/classifications/icd10/browse/2010/en#/II>

2 Not-applicable



3 Survival estimate is not age-standardised because of small numbers of patients diagnosed in the period

MORTALITY

Mortality statistics are provided by the Northern Ireland General Registrar's Office. In 2012-2016 there were on average 2,256 male and 2,043 female deaths from malignant cancer each year. The most common cause of cancer death among males was lung cancer followed by prostate cancer and colorectal cancer (Fig. 9), while among women the most common cause of cancer death was lung cancer followed by breast cancer (Fig. 10).

Figure 9: The most common cancer deaths in men: average annual deaths 2012-2016. Multiple myeloma, mesothelioma, and malignant melanoma included in 'other'.

Figure 10: The most common cancer deaths in women: average annual deaths 2012-2016. Bladder, multiple myeloma, head and neck, cervix, malignant melanoma included in 'other'.




Mortality trends

Over the ten years to 2016 the number of cancer deaths increased by 16% from 2,024 among men and 1,795 among women in 2007 to 2,298 among men and 2,122 among women in 2016 (14% increase in men, 18% in women)

When adjusted for age and population change, cancer mortality rates during 1993-2016 decreased per year by 1.0% in males, and 0.4% in females. Trends in cancer death varied by cancer site. Among men, mortality rates decreased for lung, prostate and colorectal cancer. Among women,

mortality rates decreased for breast and colorectal cancer but increased for lung cancer.

Figure 11: Trends in cancer mortality rates by sex: 1993-2016



PREVALENCE

At the end of 2016 there were 61,038 people living in NI who had been diagnosed with cancer within the previous twenty-four years (Table 8). Of these, 43.7% were male, 47.4% were aged 70 and over and 10.9% had been diagnosed in the previous year.

Table 8: Number of people living with cancer at the end of 2016 who were diagnosed within the past twenty-four years by time since diagnosis

Sex	Age at end of 2016	Time since diagnosis				24-year Prevalence
		0-1 year	1-5 years	5-10 years	10-24 years	
Male	0-69	1,741	4,622	3,219	2,971	12,553
	70+	1,540	4,267	4,063	4,263	14,133
	All ages	3,281	8,889	7,282	7,234	26,686
Female	0-69	2,075	6,221	5,258	5,980	19,534
	70+	1,272	3,737	3,552	6,257	14,818
	All ages	3,347	9,958	8,810	12,237	34,352
Both sexes	0-69	3,816	10,843	8,477	8,951	32,087
	70+	2,812	8,004	7,615	10,520	28,951
	All ages	6,628	18,847	16,092	19,471	61,038

Among men, prostate cancer was the most prevalent cancer accounting for 37% of total prevalence (Fig. 12). This was followed by colorectal cancer (18%) and lymphoma (7%). Among women, breast cancer (45%) was most prevalent followed by colorectal cancer (11%) and malignant melanoma (8%) (Fig. 13).

Figure 12: The number of male cancer patients alive on 31st December 2016 diagnosed since 1993 (24-year prevalence) by cancer site





Figure 13: The number of female cancer patients alive on 31st December 2016 diagnosed since 1993 (24-year prevalence) by cancer site



Background notes

ICD10 Topography Codes

The classification of tumour sites is carried out using ICD10 codes. For a listing and explanation of ICD10 topography or site codes see: International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, World Health Organisation, Geneva. Or view online at <http://apps.who.int/classifications/icd10/browse/2010/en#/I>

Age Standardised Incidence Rate

An age-standardised incidence rate per 100,000 persons is an estimate of the incidence rate if that population had a standard population age structure. Eighteen or nineteen age-group specific incidence rates are weighted by standard weights of the Standard Population, and summed to give the age-standardised rate. Commonly used Standard Populations (with number of age groups) are the 1976 European Standard Population (18), 2013 European Standard Population (19), and the World Standard Population (18). Standardising to a common Standard Population allows comparisons of incidence rates to be made between different time periods and geographic areas.

Standardised Incidence Ratio (SIR)

The ratio of the number of cases observed in a given population to the number of cases expected if the age-groups specific rates of a reference population were operative. This statistic is often used to compare if smaller geographic units (e.g. Trust areas) incidence rates differ from the national incidence rates, (e.g. Northern Ireland in these statistics), which is taken as the reference. An SIR of 100% indicates no difference.

Confidence Intervals (CI)

Confidence intervals are a measure of the precision of a statistic (e.g. lung cancer incidence rate). Typically, when numbers are low, precision is poorer and confidence intervals will be wider. As a general rule, when comparing statistics (e.g. cervical cancer incidence rate in year 2012 vs year 2013), if the confidence interval around one statistic overlaps with the interval around another, it is unlikely that there is any real difference between the two.

Lifetime risk

Lifetime risk is estimated as the cumulative risk of getting cancer up to age 75 (life expectancy for a typical person) using the age-specific cancer incidence rates according to this formula: $\text{cumulative risk} = 1 - \exp(-\text{sum}(\text{rates from age 1-74}))$. This method was proposed by Day (Day, 1987. Cumulative rates and cumulative risk. In Cancer Incidence in Five Continents, Muir C, Waterhouse J, Mack T, Powell J, Whelan S [eds] vol. V, pp 787-789. International Agency for Research on Cancer. IARC Scientific Publications No. 88: Lyon), and represents the lifetime risk of developing cancer when competing risks are ignored. Although this is currently the standard statistic for estimating lifetime risk of developing cancer, there are other methods which employ death information to address competing risk (see: Sasieni PD, Shelton J, Ormiston-Smith N, Thomson CS, Silcocks PB, 2012. What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries. British Journal of Cancer 105, 460-465). The odds of developing the disease before age 75 is the inverse of the cumulative risk.

Geographic Areas

Geographic areas are assigned based on a patient's postcode of usual residence at diagnosis using the Central Postcode Directory (CPD) produced by the NI Statistics and Research Agency (available at www.nisra.gov.uk)

Deprivation Quintiles

Super output areas (SOA), or 897 census output areas of NI, are assigned to each patient based on their postcode of usual residence at diagnosis. The patient is then assigned, through its SOA, to a socio-economic deprivation quintile based on the SOA's 2017 Income domain of the Multiple Deprivation Measure. The 2017 Multiple Deprivation Measure is available from the NI Statistics and Research Agency (www.nisra.gov.uk)

Prevalence of patients who have had a diagnosis of cancer

Prevalence is the number of cancer-diagnosed patients who are alive in the population on a specific date, e.g. 31st December 2016. If the Registry is recently established, there will be patients in the population diagnosed prior to establishment who were not registered by the Registry; hence the prevalence will be underestimated, and more so in good-prognosis cancers. An 'x'-year prevalence, e.g. 20-year prevalence, is defined as the number of patients that were diagnosed in a 'x'-year period (prior to a time point) and alive at that time point. 'x'-year prevalence can be used between registries of differing ages to measure the survivorship associated with a certain type of cancer. Age in the prevalence table refers to the age of patients on the 31st December 2016, not age at cancer diagnosis.

Net Survival

Net Survival is an estimate of survival where the effect on survival of background population mortality rates has been removed. As background population mortality rates, as presented in a life table, are a good approximation to the non-cancer related death rates among cancer patients, the net survival represents the [theoretical] survival of cancer patients if they could only die from cancer-related causes. Net survival is suitable for comparison of survival between different time periods and populations, as the confounding effect of non-cancer death rates is removed. Age-standardised net survival estimates are the estimates that would occur if that population [of cancer patients] had a standard population age structure. Five age-group specific survival estimates are weighted by standard weights, and summed to give the age-standardised survival estimate. The age groups and weights used here are those defined by EURO CARE, an international study group that compares cancer survival among European countries (Corazziari I, Quinn M, Capocaccia R, 2004. Standard cancer patient population for age standardising survival ratio. European Journal of Cancer 40: 2307-2316). The weights reflect the age-structure of cancer patients and can differ between cancer sites. Due to small numbers in NI for many cancer sites, the two youngest age-groups have been combined, as well as their weights, in the estimation of age-standardised net survival.

Mortality

Information relating to cancer mortality is sourced from GRONI and is based upon the date on which death occurs. Results may thus differ slightly than those produced by the Northern Ireland Statistics and Research Agency (NISRA), which produces deaths data based upon the date on which the death is registered with GRO.

FURTHER INFORMATION

Further data is available from the Northern Ireland Cancer Registry web site: www.qub.ac.uk/nicr

NI Cancer Registry

Phone: +44 (0)28 9097 6028
e-mail: nicr@qub.ac.uk



ACKNOWLEDGEMENTS

NICR is funded by the Public Health Agency and is hosted by Queen's University, Belfast. This work uses data provided by patients and collected by the NHS as part of their care and support.



**QUEEN'S
UNIVERSITY
BELFAST**